No difference in cardiovascular risk of tocilizumab vs abatacept for rheumatoid arthritis: A multi-database cohort study
Seminars in Arthritis and Rheumatism Mar 29, 2018
Kim SC, et al. - This trial encompassed a comparative scrutiny of tocilizumab vs abatacept in patients with rheumatoid arthritis (RA) in order to determine their cardiovascular safety. It was discovered that the risk of the composite cardiovascular events was similar between the two groups, with a combined hazard ratio (HR) of 0.82 in tocilizumab vs abatacept starters.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
